Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company, the Offeror or the Offeree nor is it a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of the Company, the Offeror or the Offeree in any jurisdiction in contravention of applicable law or regulation.

This announcement is not for release, publication or distribution, in whole or in part, in, into or from any jurisdiction where to do so would constitute a violation of the Applicable Laws of such jurisdiction.

HANGZHOU TIGERMED CONSULTING CO., LTD.
杭州泰格醫藥科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 3347)

PROGRESS ANNOUNCEMENT
DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE PRIVATIZATION AND SEPARATION TRANSACTION OF FRONTAGE HOLDINGS CORPORATION

Reference is made to the announcement dated November 9, 2026 (the "**Announcement**") of Hangzhou Tigermed Consulting Co., Ltd. (the "**Company**") in relation to the Proposal and the Separation Transaction (the "**Transactions**") of Frontage Holdings Corporation ("**Frontage Holdings**"), a subsidiary of the Company. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

Based on the relevant audit report provided by Frontage Holdings, the key audited financial data of Frontage Holdings for the year ended December 31, 2025 and the six months ended June 30, 2026 are set forth below:

Unit: USD'000

Items	**As at December 31, 2025/for the year ended December 31, 2025** *(Audited)*	**As at June 30, 2026/for the six months ended June 30, 2026** *(Audited)*
Total Assets	541,024	580,474
Total Liabilities	192,978	224,248
Net Assets	348,046	356,226
Operating Revenue	256,691	148,190
Net Profit	6,762	6,788

The Transactions are subject to the fulfillment of Pre-Conditions and Conditions precedent and may or may not proceed. Shareholders and potential investors of the Company, the Offeror or the Offeree are advised to exercise caution when dealing in the securities of the Company, the Offeror or the Offeree.

By Order of the Board of Directors of
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, November 17, 2026

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu; the employee Director is Mr. Wu Hao; the independent nonexecutive Directors are Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu, Paul Yu Hay.